{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:08:13Z","timestamp":1779433693432,"version":"3.53.1"},"reference-count":36,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"5","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: To measure the levels of T-cell subsets and\ncytokines in the peripheral blood of patients with systemic\nvascular inflammatory disease and to analyse the influence\nof different clinical characteristics of systemic vascular\ninflammatory disease patients on the levels of T-cell subsets\nand cytokines in the peripheral blood.\nMethods: The case group included 80 patients with systemic\nvascular inflammatory disease who were diagnosed and trea -\nted at our hospital between January 2021 and December\n2024. The control group consisted of 40 healthy volunteers\nrecruited from our hospital\u2019s health assessment centre. The\nproportions of helper T-cell (Th)1, Th17, and regulatory Tcell (Treg) subsets in peripheral blood were analysed using\nflow cytometry. Serum levels of cytokine, including interleukin-2 (IL-2), interferon-g (IFN-&lt;span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\"&gt;\u03b3&lt;\/span&gt;), tumour necrosis factor-a\n(TNF-&lt;span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\"&gt;\u03b1&lt;\/span&gt;), IL-4, IL-10, IL-17, and IL-6, were measured using\nenzyme-linked immunosorbent assay (ELISA).\nResults: Compared with the control group, the expression\nlevels of total T lymphoid subsets and CD8+ T and Th1 cells\nin patients with systemic vascular inflammatory disease were\nsignificantly higher, and there was no statistically significant\ndifference in Th, Th17, or Treg cell expression between the\ngroups (P&amp;gt;0.05). However, there were statistically significant\ndifferences between the two groups [68.75 (54.23, 80.32)]\nand [72.10 (62.23, 86.45)], [23.44 (12.89, 33.76)] and\n[31.46 (20.13, 45.26)], [10.67 (8.23, 12.35)] and [10.26,\n17.96 [25.39)], Z=-3.13, -4.54, -3.97 (all P values&amp;lt;0.05).\nCompared with those in the control group, patients with systemic vascular inflammatory disease had significantly higher\nserum levels of IL-17, IL-6, TNF-&lt;span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\"&gt;\u03b1&lt;\/span&gt;, IL-4, and IFN-&lt;span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\"&gt;\u03b3&lt;\/span&gt;, whereas\ntheir IL-10 levels were significantly lower. The differences\nwere statistically significant (Z=-4.32, -5.01, -8.18, -8.70,\n-3.48, and -8.30). The P values were all &amp;lt;0.05. Compared\nwith that in patients without related manifestations, IL-6\nexpression was noticeably higher in systemic vascular inflammatory disease patients with arthritic symptoms and those\nwith active systemic vascular inflammatory disease, and the\ndifference was statistically significant {pg\/mL: [3.23 (2.98,\n5.35)] compared with [10.51 (6.72, 23.21)], [6.32 (4.79,\n8.93)] compared with [9.68 (6.97, 18.73)], Z=5.47, 8.76,\nP values &amp;lt;0.05}. Compared with those in patients without\nrelevant clinical manifestations, TNF-&lt;span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\"&gt;\u03b1&lt;\/span&gt; levels were significantly higher in patients with arthritis, ocular, or digestive tract\nmanifestations, and in patients with active systemic vascular\ninflammatory disease, whereas IFN-&lt;span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\"&gt;\u03b3&lt;\/span&gt; levels were substantially\nhigher in systemic vascular inflammatory disease patients\nwith digestive system lesions. The differences were statistically significant {pg\/mL: [7.74 (6.89, 10.19)] compared with\n[39.84 (30.37, 50.61)], [6.12 (5.36, 9.89)] compared with\n[31.35 (15.71, 30.46)], [6.49 (4.78, 10.21)] compared\nwith [19.89 (14.36, 36.21)]. [5.89 (4.61, 8.96)] than\n[27.91 (15.32, 37.81)], [6.89 (5.43, 14.86)] than [26.79\n(15.41, 31.56)], Z= 7.70, 6.84, 6.94, 9.47, 5.70, P values\n&amp;lt;0.05}. However, there was no statistically significant difference in the expression levels of IL-4 and IL-17 between systemic vascular inflammatory disease patients with and without relevant clinical manifestations (P&amp;gt;0.05).\nConclusions: Patients with systemic vascular inflammatory\ndisease exhibit an imbalance of T lymphocyte subsets and\ncytokines, and disease activity and clinical classification\nmay also involve such imbalances.<\/jats:p>","DOI":"10.5937\/jomb0-61241","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T09:37:53Z","timestamp":1763026673000},"page":"988-997","source":"Crossref","is-referenced-by-count":0,"title":["Correlation analysis of cytokine levels and peripheral blood T lymphocyte subsets in systemic vascular inflammatory disease"],"prefix":"10.5937","volume":"45","author":[{"given":"Zhonghan","family":"Lin","sequence":"first","affiliation":[{"name":"Nanjing Medical University, Clinical College of Nanjing Medical University, Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyang","family":"Dong","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University, Laboratory Department, First Affiliated Hospital, No. 58, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junye","family":"Chen","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University, Laboratory Department, First Affiliated Hospital, No. 58, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Li","sequence":"additional","affiliation":[{"name":"The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Department of Cardiology, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Lavalle S, Caruso S, Foti R, Gagliano C, Cocuzza S, La Via L, Parisi FM, Calvo-Henriquez C, Maniaci A. Behcet's Disease, Pathogenesis, Clinical Features, and Treatment Approaches: A Comprehensive Review. Medicina (Kaunas) 2024 Mar 29; 60(4): 562. doi: 10.3390\/medicina60040562. PMID: 38674208; PMCID: PMC11051811;","DOI":"10.3390\/medicina60040562"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Zhong Z, Su G, Yang P. Risk factors, clinical features and treatment of Behcet's disease uveitis. Prog Retin Eye Res 2023 Nov; 97: 101216. doi: 10.1016\/j.preteyeres.2023.101216. Epub 2023 Sep 19. PMID: 37734442;","DOI":"10.1016\/j.preteyeres.2023.101216"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Alharthy F, Almaqati AS, Alsulami S, Ahmad A. Behcet's Disease in Saudi Arabia: Clinical and Demographic Characteristics. Cureus 2023 Feb 11; 15(2): e34867. doi: 10.7759\/cureus.34867. PMID: 36923194; PMCID: PMC10010633;","DOI":"10.7759\/cureus.34867"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Bergamo S. The diagnosis of Adamantiades-Beh\u00e7et disease: Clinical features and diagnostic\/classification criteria. Front Med (Lausanne) 2022 Dec 9; 9: 1098351. doi: 10.3389\/fmed.2022.1098351. PMID: 36569165; PMCID: PMC9780472;","DOI":"10.3389\/fmed.2022.1098351"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Ding Y, Hu W, Li L, Guan W, Guan K, He Y, Liu S, Li TF. Clinical features and independent predictors of Behcet's disease associated with myelodysplastic syndrome. Clin Exp Rheumatol 2023 Sep; 41(9): 1823-30. doi: 10.55563\/clinexprheumatol\/04us5e. Epub 2023 Feb 7. PMID: 36762734;","DOI":"10.55563\/clinexprheumatol\/04us5e"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Kidd DP. Neurological involvement by Behcet's syndrome: clinical features, diagnosis, treatment and outcome. Pract Neurol 2023 Oct; 23(5): 386-400. doi: 10.1136\/pn-2023-003875. Epub 2023 Sep 29. PMID: 37775123;","DOI":"10.1136\/pn-2023-003875"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Zhan H, Cheng L, Li Y. Neuro-Beh\u00e7et's disease: an update of clinical diagnosis, biomarkers, and immunopathogenesis. Clin Exp Immunol 2025 Jan 21; 219(1): uxae123. doi: 10.1093\/cei\/uxae123. PMID: 39774671; PMCID: PMC11755846;","DOI":"10.1093\/cei\/uxae123"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Tono T, Kikuchi H, Sawada T, Takeno M, Nagafuchi H, Kirino Y, Tanaka Y, Yamaoka K, Hirohata S. Clinical features of Behcet's disease patients with joint symptoms in Japan: A national multicenter study. Mod Rheumatol 2022 Oct 15; 32(6): 1146-52. doi: 10.1093\/mr\/roab092. PMID: 34850090;","DOI":"10.1093\/mr\/roab092"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"\u00c7akan ZK, Ya\u0131z B, Pehlivan Y. Clinical features of Behcet's disease and prediction of the use of biologics in 488 cases: a single tertiary center study. Rheumatol Int 2023 Nov; 43(11): 2089-97. doi: 10.1007\/s00296-023-05416-0. Epub 2023 Aug 22. PMID: 37604938;","DOI":"10.1007\/s00296-023-05416-0"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Konak HE, Erden A, Arma\u011fan B, G\u00fcven SC, Apayd\u0131n H, Dal\u0131 PA, Uzun Y, Kayg\u0131s\u0131z M, K\u00fc\u00e7\u00fck\u015fahin O, Omma A. Effects of breast milk on Behcet's disease clinical features. Turk J Med Sci 2023 Feb; 53(1): 121-9. doi: 10.55730\/1300-0144.5565. Epub 2023 Feb 22. PMID: 36945965; PMCID: PMC10387996;","DOI":"10.55730\/1300-0144.5565"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV\/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY) 2021 Apr 20; 13(8): 10833-52. doi: 10.18632\/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137;","DOI":"10.18632\/aging.202860"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Rom\u00e3o VC, Khmelinskii N. Clinical and ultrasonographic features of erythema nodosum in Behcet's disease. Rheumatology (Oxford) 2022 Aug 3; 61(8): e254. doi: 10.1093\/rheumatology\/keac035. PMID: 35048944;","DOI":"10.1093\/rheumatology\/keac035"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Al-Omoush O, AlBarakat MM, Alasmar D, Al-Khalaileh A, Alzoubi A, Tarakhan H, Shakhatreh Z, Hatamleh Z, Abu-Saleh M, Saleh O, Altiti A, Hazaymeh W, Alshwayyat S, Hanifa H, Hazaimeh E. Clinical and imaging features of parenchymal and nonparenchymal neuro-Beh\u00e7et's disease: a systematic review of case reports and series. BMC Neurol 2025 May 26; 25(1): 225. doi: 10.1186\/s12883-025-04250-0. PMID: 40419971; PMCID: PMC12107814;","DOI":"10.1186\/s12883-025-04250-0"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines 2022 Sep 10; 10(9): 2248. doi: 10.3390\/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572;","DOI":"10.3390\/biomedicines10092248"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Lee S, Kang S, Eun Y, Kim H, Lee J, Koh EM, Kim DK, Cha HS. Clinical characteristics and radiographic outcomes of vascular Behcet's disease involving the aorta or its major branches. Clin Rheumatol 2022 Jun; 41(6): 1769-77. doi: 10.1007\/s10067-021-06031-9. Epub 2022 Feb 7. PMID: 35128590;","DOI":"10.1007\/s10067-021-06031-9"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Trigianese P, Vitale A, Lopalco G, Mayrink Giardini HA, Ciccia F, Al-Maghlouth I, Ruscitti P, Sfikakis PP, Iannone F, de Brito Antonelli IP, Patrone M, Asfina KN, Di Cola I, Laskari K, Gaggiano C, Tufan A, Sfriso P, Dagna L, Giacomelli R, Hinojosa-Azaola A, Ragab G, Fotis L, Direskeneli H, Spedicato V, Dagostin MA, Iacono D, Ali HH, Cipriani P, Sota J, Kardasini RC, Bindoli S, Campochiaro C, Navarini L, Gentileschi S, Mart\u00edn-Nares E, Torres-Ruiz J, Saad MA, Kourtesi K, Alibaz-Oner F, Sevik G, Iagnocco A, Makowska J, Govoni M, Monti S, Maggario MC, La Torre F, Del Giudice E. Intern Emerg Med 2023 Nov; 18(8): 2231-43. doi: 10.1007\/s11739-023-03408-3. Epub 2023 Oct 12. Erratum in: Intern Emerg Med 2024 Jan; 19(1): 255-257. doi: 10.1007\/s11739-023-03511-5. PMID: 37828268; PMCID: PMC10635948;","DOI":"10.1007\/s11739-023-03511-5"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines 2023 Jun 29; 11(7): 1861. doi: 10.3390\/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220;","DOI":"10.3390\/biomedicines11071861"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Casares-Marfil D, Esencan D, Alibaz-Oner F, \u00c7efle A, Yaz\u0131c\u0131 A, Duzgun N, Ayk MA, \u00d6zbek S, Cinar M, Alpsoy E, Bilge SY, Kasifoglu T, Saruhan-Direskeneli G, Direskeneli H, Sawalha AH. Clinical trait-specific genetic analysis in Behcet's disease identifies novel loci associated with ocular and neurological involvement. Clin Immunol 2023 Aug; 253: 109657. doi: 10.1016\/j.clim.2023.109657. Epub 2023 Jun 2. PMID: 37271218; PMCID: PMC10529450;","DOI":"10.1016\/j.clim.2023.109657"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Zhang B, Yang Y, Kuang T, Xu Z, Gong J. Analysis of clinical and imaging features of Behcet's disease-related pulmonary lesions: A series of eight cases. Chin Med J (Engl). 2022 Aug 20; 135(16): 2011-3. doi: 10.1097\/CM9.0000000000002338. PMID: 36378138; PMCID: PMC9746756;","DOI":"10.1097\/CM9.0000000000002338"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: Construction of a prognostic model. Anticancer Drugs 2022 Jan 1; 33(1): e590-e603. doi: 10.1097\/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349;","DOI":"10.1097\/CAD.0000000000001189"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz SA, Kostianovsky A, Allievi A, Orden AO. Behcet disease in Latin American countries: A systematic literature review of demographic and clinical features, and HLA-B*51 allele frequency. Reumatol Clin (Engl Ed) 2023 Aug-Sep; 19(7): 386-91. doi: 10.1016\/j.reumae.2022.12.005. PMID: 37661116;","DOI":"10.1016\/j.reuma.2022.12.005"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Wu YC, Fu YJ, Xia HJ, Zhu J, Huang Y, Jiang ZN. Ileocecal involvement in intestinal Behcet's disease and Crohn's disease: Comparison of clinicopathological and immunophenotypic features. J Dig Dis 2023 Nov; 24(11): 594-602. doi: 10.1111\/1751-2980.13236. Epub 2023 Nov 21. PMID: 37864553;","DOI":"10.1111\/1751-2980.13236"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Ding X, Yang J, Han X, Shen YF, Yang K, Shangguan Y, Dong Y, Ye X. Clinical features and novel pathogenic variants of patients with Behcet's disease like trisomy 8. Orphanet J Rare Dis 2025 Jul 4; 20(1): 340. doi: 10.1186\/s13023-025-03878-y. PMID: 40616106; PMCID: PMC12228353;","DOI":"10.1186\/s13023-025-03878-y"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs 2022 Oct 1; 33(9): 943-59. doi: 10.1097\/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295;","DOI":"10.1097\/CAD.0000000000001319"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Liu Z, Yang C, Bai X, Shen K, Qiao L, Wang Q, Yang H, Qian J. Clinical features and prognosis of patients with gastrointestinal Behcet's disease-like syndrome and myelodysplastic syndrome with and without trisomy 8. Semin Arthritis Rheum 2022 Aug; 55: 152039. doi: 10.1016\/j.semarthrit.2022.152039. Epub 2022 Jun 3. PMID: 35689913;","DOI":"10.1016\/j.semarthrit.2022.152039"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"G\u00fcrel Bedir A, Kilic SS. Clinical characteristics and quality of life in children with PFAPA syndrome and Behcet's disease. Rheumatol Adv Pract 2025 Feb 11; 9(1): rkaf015. doi: 10.1093\/rap\/rkaf015. PMID: 39959133; PMCID: PMC11829805;","DOI":"10.1093\/rap\/rkaf015"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Ruscitti P, Natoli V, Consolaro A, Caorsi R, Rosina S, Giancane G, Naddei R, Di Cola I, Di Muzio C, Berardicurti O, Iacono D, Pantano I, Rozza G, Rossi S, De Stefano L, Balduzzi S, Vitale A, Caso F, Costa L, Prete M, Navarini L, Iagnocco A, Atzeni F, Guggino G, Perosa F, Cantarini L, Frediani B, Montecucco C, Ciccia F, Cipriani P, Gattorno M, Giacomelli R, Ravelli A. Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. Rheumatology (Oxford) 2022 Oct 6; 61(10): 4124-9. doi: 10.1093\/rheumatology\/keac027. PMID: 35078234; PMCID: PMC9536787;","DOI":"10.1093\/rheumatology\/keac027"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Yoo JW, Jo SI, Shin DW, Park JW, Kim SE, Lim H, Kang HS, Moon SH, Kim MK, Kim SY, Hwang SW, Soh JS. Clinical Usefulness of Immune Profiling for Differential Diagnosis between Crohn's Disease, Intestinal Tuberculosis, and Behcet's Disease. Diagnostics (Basel) 2023 Sep 11; 13(18): 2904. doi: 10.3390\/diagnostics13182904. PMID: 37761270; PMCID: PMC10529363;","DOI":"10.3390\/diagnostics13182904"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Murakami K, Arai J, Ihara S, Tsuchida Y, Shoda H, Tsuboi M, Kurokawa K, Shiomi C, Suzuki N, Hayakawa Y, Fujio K, Fujishiro M. Upper gastrointestinal involvement of Behcet's disease in Japan: Endoscopic findings and clinical features. J Gastroenterol Hepatol 2024 Apr; 39(4): 708-15. doi: 10.1111\/jgh.16479. Epub 2024 Jan 7. PMID: 38185774;","DOI":"10.1111\/jgh.16479"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Makkawi S, Aljafari D, Alsharif R, Maaddawi H, Alwagdani A, Aljumah T, Alghweinem Z, Alshehri S, Khojah O, Halawani A, Ahmed Adas R, Abulaban A, Al Malik Y. The clinical and radiological features and prevalence of Neuro-Beh\u00e7et's Disease: A retrospective cohort multicenter study in Saudi Arabia. Mult Scler Relat Disord 2024 May; 85: 105558. doi: 10.1016\/j.msard.2024.105558. Epub 2024 Mar 20. PMID: 38569381;","DOI":"10.1016\/j.msard.2024.105558"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Zhou J, Zhang D, Wang Z, Hou Y, Liu J, Zeng X, Wang Y, Zheng W. The clinical features, image findings and risk factors for vena cava syndrome in Behcet's syndrome. Clin Exp Rheumatol 2022 Sep; 40(8): 1526-34. doi: 10.55563\/clinexprheumatol\/r6her6. Epub 2022 Jul 11. PMID: 35819814;","DOI":"10.55563\/clinexprheumatol\/r6her6"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Li Y, Xiong Z, Jiang Y, Shen Y, Hu X, Hu D, Li Z. Enhancing the Differentiation between Intestinal Behcet's Disease and Crohn's Disease through Quantitative Computed Tomography Analysis. Bioengineering (Basel) 2023 Oct 17; 10(10): 1211. doi: 10.3390\/bioengineering10101211. PMID: 37892941; PMCID: PMC10604024;","DOI":"10.3390\/bioengineering10101211"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Prtenja~a L, Mayer M, Karanovi\u0107 B, Rukavina K, Bakula M, Padjen I, \u0160epovi\u0107-Ljucovi\u0107 M, Tomi\u0107evi\u0107 LS, Ani\u0107 B, Bare\u0161i\u0107 M. Demographics and clinical manifestations in patients with Behcet's disease: A retrospective observational study from a nonendemic country. Rheumatol Int 2025 Apr 15; 45(5): 102. doi: 10.1007\/s00296-025-05855-x. PMID: 40232346;","DOI":"10.1007\/s00296-025-05855-x"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Kaymaz S, Ayd\u0131n D, Uur K, \u00c7obankara V, Tan S. Expression Levels and Clinical Values of miR-195, miR-424, miR-10b, miR-103a-3p, and miR-542-3p in Vasculo-Beh\u00e7et's Disease. Mediterr J Rheumatol 2023 Sep 7; 35(2): 255-62. doi: 10.31138\/mjr.030623.elc. PMID: 39211027; PMCID: PMC11350416;","DOI":"10.31138\/mjr.030623.elc"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Elidrissi EH, Elaissat EM, Assoufi N, Tbouda M. Association of Sweet's Syndrome and Behcet's Disease: Is It Possible? A Case Report. Eur J Case Rep Intern Med 2023 Sep 19; 10(10): 004073. doi: 10.12890\/2023_004073. PMID: 37789984; PMCID: PMC10545150;","DOI":"10.12890\/2023_004073"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Park Y, Ahn JB, Kim DH, Park IS, Son M, Kim JH, Ma HW, Kim SW, Cheon JH. Integrated Analysis of Microbiome and Metabolome Reveals Disease-Specific Profiles in Inflammatory Bowel Diseases and Intestinal Behcet's Disease. Int J Mol Sci 2024 Jun 18; 25(12): 6697. doi: 10.3390\/ijms25126697. PMID: 38928402; PMCID: PMC11203907;","DOI":"10.3390\/ijms25126697"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Analiza povezanosti nivoa citokina i subpopulacija T limfocita u perifernoj krvi kod sistemskih vaskularnih zapaljenskih oboljenja"],"language":"en","link":[{"URL":"https:\/\/aseestant.ceon.rs\/index.php\/jomb\/article\/download\/61241\/29310","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582605988L.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:43:13Z","timestamp":1779432193000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582605988L"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-61241","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}